Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

Abstract

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

“…Chronic P. aeruginosa infection is typically treated with chronic inhaled antibiotics to suppress infection, reduce risk of pulmonary exacerbations, improve quality of life, and preserve lung function 5,6 .…”

Early Childhood Risk Factors for Decreased FEV1at Age 6-7 Years in Young Children with Cystic Fibrosis

“…Previous studies have identified risk factors for low FEV 1 % predicted at age 6, including female sex, poor nutritional status, viral infections, persistent infection with Pseudomonas aeruginosa (P. aeruginosa), respiratory symptoms, pulmonary exacerbations, and low socioeconomic status (3)(4)(5)(6)(7)(8). It is unclear whether these risk factors remain applicable in the current era, as children with CF born today are more likely to be detected by newborn screening (NBS) and treated more aggressively with antibiotics and CF-specific therapies, and to undergo eradication therapy when P. aeruginosa is isolated from respiratory cultures (9)(10)(11).…”

Клінічне Спостереження Дитини, Хворої На Муковісцидоз

“…Легеневі загострення обумовлюють несприятливий вплив на якість життя пацієнтів і мають вагому частку в загальній вартості медичного обслуговування [5,6].…”